Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
8.08
+0.58 (7.73%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Akari Therapeutics, Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Akari Therapeutics, stock has a consensus rating of "Buy" and an average price target of $28.39. The average 1-year stock price forecast is 251.36% higher than the current stock price, while the lowest is $26.78 (+231.44%) and the highest is $30 (+271.29%).
Price Target: $28.39 (+251.36%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Akari Therapeutics, stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 2 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Upgrades $30 | Buy | Upgrades | $30 | +271.29% | Jul 20, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $27 | Buy | Reiterates | $27 | +234.16% | Jul 1, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-12.00
from -0.01
EPS Next Year
-14.00
from -12.00
EPS and Forward PE are based on non-GAAP adjusted numbers.